

PLATFORM
Powering the future of
immune-mediated inflammatory disease (IMID) medicines
Discovering and developing the next generation of medicines for IMIDs
PATIENT-BASED DISCOVERY
Our Clinical Discovery Engine directly addresses one of the greatest risks to health today
At IMIDomics, our discovery process begins and ends with the patients. Our Engine uses state-of-the-art discovery tools combined with the highest quality patient data, omics, analytical tools, and a deep understanding of IMIDs. Our multidimensional approach is required to characterize their multiple forms and complexity at the individual and patient group levels.

Currently FOCUSing ON eight diseases
Systemic Lupus Erythematosus
Ulcerative Colitis
Crohn’s Disease
Rheumatoid Arthritis
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Sjögren’s Syndrome
CLINICAL DISCOVERY ENGINE
Our Engine combines the collection, generation, and analysis of data to drive more efficient drug development
CLINICAL NETWORK
Our network of clinicians and academic partners give us unprecedented access to patient data and samples
Our work is enabled by an investigator network across Spain. They follow a common protocol, and data are audited and curated to ensure validity, quality, and comparability. Samples are stored in the ISO-certified IMID Biobank. Patient identity for all data and samples is anonymized prior to transfer to IMIDomics in compliance with GDPR regulations.
BIOBANK
- >17,000 subjects
- Cross-sectional and longitudinal
- >1M sample vials of biological specimens
- Every subject donates whole blood and urine
- Biopsies from select subjects
Direct investigator engagement
Protocols developed in collaboration with KOLs
Epidemiological and Clinical Data
- >15,000 clinical variables
- >150 epidemiological variables
- 2M epidemiological and clinical data points collected
- Collected for every subject
Selection of most informative patients
Ability to follow up with subjects
DATA GENERATION
We use the most advanced bio-analytical methods to probe mechanisms driving disease
The following data are collected and combined into a proprietary database of more than 14 terabytes which allows interrogation and analysis across all datatypes on a single-patient basis or across the whole collection of subjects.
GWAS
Bulk RNA-seq
Proteomics
Epigenetics
Single-cell data

TARGET DISCOVERY
This allows us to match the right drug target to the right patient
Our approach personalizes treatment by matching patients with the right drug targets. Using multidimensional patient data and machine learning, we uncover underlying disease processes, identify common mechanisms, and categorize patients into subgroups. This reveals new insights for target discovery and helps assess their applicability across multiple IMIDs.
Integrated, multidimensional analysis applied to reliable data yields innovative targets and relevant patient populations
Define diseases at the single cell level
Leverage genetic architecture to identify causal mechanisms
Characterization of large patient cohorts
Untangle genetic profiles to stratify patient populations
.gif)
DOCTIS
Decision on optimal combinatorial Therapies in IMIDs using Systems Approaches
European Union Horizon 2020 Research and Innovation Programme
Coordinator: Dr. Sara Marsal
To discover effective drug combinations to treat IMID patients based on:
Coordinator: Dr. Sara Marsal
To discover effective drug combinations to treat IMID patients based on:
- Patient medical and epidemiological data
- Multi-omic patient analyses
- Bioinformatics
- Preclinical and clinical experimentation

Discovering and developing the next generation of medicines for immune-mediated inflammatory diseases